MeSH tree: C14.907.454.460
People diagnosed with multiple myeloma—one of the most common forms of blood cancer—are now living nearly twice as long on average as they were in 2005, according to a new study.
Sep 4, 2025
0
15
Patients are increasingly turning to AI for medical information and even advice, but how should they approach using AI-powered services? A new study published Sept. 3 in the journal Future Science OA, provides insight into ...
Sep 3, 2025
0
17
A team of researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has successfully treated a rare and aggressive T-cell lymphoma that developed after CAR T-cell therapy for multiple myeloma, ...
Aug 21, 2025
0
42
A new study focused on multiple myeloma, the second most common blood cancer, may lead to better ways to group patients by the state of their DNA and define new subtypes of disease to better predict treatment strategies and ...
Aug 21, 2025
0
22
Researchers have created the first detailed molecular map of the human bone marrow, revealing new insights that could reshape our thinking about how an incurable blood cancer grows and spreads.
Aug 18, 2025
0
30
Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions. The new method, known as SWIFT-seq, utilizes ...
Aug 8, 2025
0
33
In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, according to a study published ...
Jul 31, 2025
0
14
Researchers at Uppsala University have identified a promising therapeutic approach for the challenging blood cancer multiple myeloma. In a new preclinical study, they demonstrate that a dual treatment with drugs that inhibit ...
Jul 24, 2025
0
19
Researchers from Helmholtz Munich and the Technical University of Munich have developed a novel method to track cancer treatment responses in individual cells—without the need for dyes or labels.
Jul 14, 2025
0
18
Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation antigen (BCMA) receptor. It received accelerated approval in 2022 for patients treated with four or more ...
Jul 9, 2025
0
19
